Printer Friendly

Treating invasive aspergillosis.

Salvage therapies in patients with invasive aspergillosis have little efficacy, so it is imperative to choose an effective initial therapy, a study led by Thomas F. Patterson, M.D., of the University of Texas, suggests.

Of 144 patients treated initially with voriconazole, 36% were switched to another licensed antifungal therapy before completion of the initial therapy, and 48% of those responded. Of 133 patients initially treated with amphotericin B, 80% were switched to another antifungal, and 38% of those responded. Switches were made because of intolerance or insufficient response in 24% of voriconazole patients, compared with 70% of amphotericin B patients (Clin. Infect. Dis. 2005;41:1448-52).

Salvage therapy response rates were poorest with lipid formulations of amphotericin B, particularly when they were used after failed amphotericin B therapy. The overall response rate to such formulations was 30%, but the response rate in those who switched due to poor response to amphotericin B was 12%.
COPYRIGHT 2005 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CLINICAL CAPSULES
Author:Worcester, Sharon
Publication:Internal Medicine News
Article Type:Brief Article
Geographic Code:1USA
Date:Dec 1, 2005
Words:155
Previous Article:Antibiotic prescribing reviewed.
Next Article:Candidemia treatment options.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters